Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJNV4O)

• Drug Name: Tirbanibulin Drug Info
• Synonyms: KX2-391; 897016-82-9; KX-01; UNII-4V9848RS5G; N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetamide; KX-2-391; CHEMBL571546; 4V9848RS5G; KX2391; KX 01; KX-2391; MLS006011272; SCHEMBL153779; KX01; GTPL7957; DTXSID30237862; MolPort-023-293-512; HUNGUWOZPQBXGX-UHFFFAOYSA-N; HMS3656J15; EX-A2434; BCP02845; ZINC43152787; s2700; BDBM50303801; AKOS027276392; KX2-391; KX-01; SB16619; CS-0248; KX2-391 (KX01); BCP9000828; 2-Pyridineacetamide, 5-(4-(2-(4-morpholinyl)ethoxy)phenyl)-n-(phenylmethyl)-; NCGC00346644-05; NCGC00346644-01; KX 2

Indication

Disease Entry	ICD 11	Status	REF
Actinic keratosis	EK90.0	Approved	[1]
Prostate cancer	2C82.0	Phase 2	[2]

• Cross-matching ID:
  PubChem CID: 23635314
  CAS Number: CAS 897016-82-9
  TTD Drug ID: DMJNV4O
  ACDINA Drug ID: D01489

Molecule-Related Drug Atlas

Drug(s) Targeting Tubulin polymerization (TubP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PM184	DMS34YO	Colorectal cancer	2B91.Z	Phase 2	[4]

Drug(s) Affected By Serine protease HTRA1 (HTRA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[3]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[5]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[6]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[7]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[8]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[9]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[10]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[11]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[3]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[3]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tubulin polymerization (TubP)	TTHVQ4N	NOUNIPROTAC	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Serine protease HTRA1 (HTRA1)	OTR8ACBF	HTRA1_HUMAN	Gene/Protein Processing	[3]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7957).
• [3] Inorganic arsenic exposure promotes malignant progression by HDAC6-mediated down-regulation of HTRA1. J Appl Toxicol. 2023 Aug;43(8):1214-1224. doi: 10.1002/jat.4457. Epub 2023 Mar 11.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [6] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [7] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [8] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [9] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
• [10] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [11] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.